Recent News

GU Symposium 2021: Neoadjuvant Durvalumab Plus Chemotherapy in Muscle-Invasive Urothelial Carcinoma

Are There Racial Disparities in BCG Treatment of Non–Muscle Invasive Bladder Cancer?

Durvalumab Indication Withdrawn in Advanced Bladder Cancer in the United States

GU Symposium 2021: Novel IL-15 Superagonist for Non–Muscle-Invasive Bladder Cancer

Does Biologic Sex Influence Progression of Bladder Cancer After BCG Treatment?

GU Symposium 2021: Enfortumab Vedotin Versus Chemotherapy for Advanced Urothelial Carcinoma

GU Symposium 2021: Impact of Gender on Surgical Outcomes After Radical Cystectomy

GU Symposium 2021: Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Cancer

Proliposomal Paclitaxel in Non–Muscle Invasive Bladder Cancer: Study Supports Move to Phase IIb

Durvalumab-Based Combination Therapy in Non–Muscle Invasive Bladder Cancer

Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma

FDA Brief: Novel Treatment of Upper Tract Urothelial Cancer Granted Fast Track Designation

Chronic Kidney Disease: Risk Factor for Muscle-Invasive Bladder Cancer?

Does Cystectomy Delay Affect Mortality in Bladder Cancer?

Neoadjuvant Chemotherapy Deferral in Patients Undergoing Cystectomy for Bladder Cancer

Are Individuals With Multiple Sclerosis at Higher Risk of Developing Bladder Cancer?

Kidney-Sparing Alternative Treatment of Low-Grade Upper Tract Urothelial Carcinoma

Are There Racial Disparities in Mortality in Muscle-Invasive Bladder Cancer?

Avelumab Plus Axitinib Under Study in Urothelial Cancer

Ureteral Obstruction Prior to Chemotherapy for Muscle-Invasive Bladder Cancer

Combination Immunotherapy for Urothelial Carcinoma: Phase Ib Interim Analysis

DDR Alterations and Outcomes With Immunotherapy for Advanced Urothelial Cancer

JAVELIN Bladder 100: Avelumab Maintenance for Advanced Urothelial Carcinoma

ADP-A2M10 Dose-Escalation Trial in MAGE-A10–Positive Urothelial Tumors

HER2-Targeting Antibody-Drug Conjugate in Advanced Urothelial Carcinoma

Are High 12-Chemokine Scores Prognostic in Muscle-Invasive Bladder Cancer?

Neoadjuvant Ipilimumab Plus Nivolumab Under Study in Urothelial Carcinoma

SITC 2020: Tumor Mutation Burden and Response to Immunotherapy in Advanced Urothelial Cancer

ASTRO 2020: Combination Radiotherapy and Durvalumab in Localized Bladder Cancer

Neoadjuvant Dual Checkpoint Blockade for High-Risk Urothelial Carcinoma

ASTRO 2020: Bladder-Sparing Radiochemotherapy Regimens Under Study

ASTRO 2020: Predicting Survival Outcomes in Bladder Cancer Using Urinary Tumor DNA

Novel Urine DNA Methylation Assay Under Study in Bladder Cancer

ASTRO 2020: Outcomes With Radiotherapy in Men and Women With Urothelial Bladder Cancer

FDA in Brief: Draft Guidance for Uniform Approach to Clinical Trials in Bladder Cancer

Extended Follow-up With Nivolumab Plus Ipilimumab in Advanced Urothelial Cancer

Enfortumab Vedotin in Previously Treated Advanced Urothelial Cancer: Update From EV-201

Concurrent Nivolumab and Radiotherapy in Elderly Patients With Bladder Cancer

ESMO 2020: Link Between TMB and Pembrolizumab Response in Urothelial Cancer?

Durvalumab Plus Cabozantinib in Advanced Urothelial Cancer: ARCADIA Trial

Whole-Genome Sequencing Via Urine: Novel Modality for Detecting Urothelial Carcinoma

Effect of Proton Pump Inhibitors on Response to Atezolizumab in Urothelial Cancer